(±)-Thalidomide, Immunomodulator and anticancer agent (ab120032)
Key features and details
- Immunomodulator and anticancer agent
- CAS Number: 50-35-1
- Soluble in DMSO to 25 mM
- Form / State: Solid
- Source: Synthetic
製品の概要
-
製品名
(±)-Thalidomide, Immunomodulator and anticancer agent -
製品の詳細
Immunomodulator and anticancer agent -
生理活性の詳細
Immunomodulator. Antiproliferative, antiangiogenic and pro-apoptotic.
-
CAS 番号
50-35-1 -
構造式
製品の特性
-
体系名
N-(2,6-Dioxo-3-piperidinyl)phthalimide -
分子量
258.23 -
分子式
C13H10N2O4 -
PubChem 登録番号
5426 -
保存方法
Store at +4°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
溶解性
Soluble in DMSO to 25 mM -
使用に関する注意
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Toxic, refer to SDS for further information.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES 線形表記
O=C1NC(=O)CCC1N3C(=O)c2ccccc2C3=O -
由来
Synthetic
-
研究分野
画像
-
Chemical Structure - (±)-Thalidomide, Immunomodulator and anticancer agent (ab120032)2D chemical structure image of ab120032, Thalidomide, Immunomodulator and anticancer agent
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
参考文献 (3)
ab120032 は 3 報の論文で使用されています。
- Bouguenina H et al. iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells. iScience 26:107059 (2023). PubMed: 37360684
- Rosa TLSA et al. The Type I Interferon Pathway Is Upregulated in the Cutaneous Lesions and Blood of Multibacillary Leprosy Patients With Erythema Nodosum Leprosum. Front Med (Lausanne) 9:899998 (2022). PubMed: 35733868
- Quayle LA et al. Anti-angiogenic drugs: direct anti-cancer agents with mitochondrial mechanisms of action. Oncotarget 8:88670-88688 (2017). PubMed: 29179466